ArticleAmyotrophic lateral sclerosis & frontotemporal degeneration2018
A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013.
Article in Amyotrophic lateral sclerosis & frontotemporal degeneration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Multidisciplinary clinic attendance and patterns of care in the U.S. National ALS Registry, 2013-2023.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2026Article
- Preparing Amyotrophic Lateral Sclerosis Clinics to Provide Longitudinal Care for Individuals Carrying ALS Risk Variants.Neurology. Genetics · 2026Article
- Approaching Serious Illness Conversations in Amyotrophic Lateral Sclerosis Using Telehealth: A Practical Guide.Neurology. Clinical practice · 2026Review
- Proximity to Healthcare Services Among Individuals With Duchenne Muscular Dystrophy.AJPM focus · 2026Article
- Amyotrophic Lateral Sclerosis Clinical Research Site Operations: Emerging Challenges and Potential Solutions From Multiple Sites in the US.Muscle & nerve · 2026Article
- The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United States.Neurology research international · 2026Article
- miRNA Biomarkers Diagnose Amyotrophic Lateral Sclerosis in Circulating Blood.Molecular neurobiology · 2025Article
- Impact of the Adverse Social Exposome on Survival in Individuals With Amyotrophic Lateral Sclerosis.Neurology · 2025Article
- Reliable monitoring of respiratory function with home spirometry in people living with amyotrophic lateral sclerosis.Frontiers in neurology · 2025Article
- Rurality modifies the association between symptoms and the diagnosis of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2024Article
- Article
- Higher Glycemic Index and Glycemic Load Diet Is Associated with Slower Disease Progression in Amyotrophic Lateral Sclerosis.Annals of neurology · 2024Article
- Adherence to practice parameters in Medicare beneficiaries with amyotrophic lateral sclerosis.PloS one · 2024Article
- Rapid LC-MS/MS quantification of Organophosphate non-specific metabolites in hair using alkaline extraction approach.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2023Article
- Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2023Article
- Telehealth-based exercise in amyotrophic lateral sclerosis.Frontiers in neurology · 2023Article
- Exploring the association between outcome measures to guide clinical management in patients with amyotrophic lateral sclerosis.Journal of physical therapy science · 2022Article
- Ten years of riluzole use in a tertiary ALS clinic.Muscle & nerve · 2022Article
- Co-cultures of cerebellar slices from mice with differentF1000Research · 2022Article
- Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism.Journal of medical Internet research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundAmyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease that typically results in death within 2-5 years of initial symptom onset. Multidisciplinary ALS clinics (MDCs) have been established to provide specialty care to people living with the disease.
objectiveTo estimate the proximity of ALS prevalence cases to the nearest MDC in the US to help evaluate one aspect of access to care.
methodsUsing 2013 prevalence data from the National ALS Registry, cases were geocoded by city using geographic information system (GIS) software, along with the locations of all MDCs in operation during 2013. Case-to-MDC proximity was calculated and analyzed by sex, race, and age group.
resultsDuring 2013, there were 72 MDCs in operation in 30 different states. A total of 15,633 ALS cases were geocoded and were distributed throughout all 50 states. Of these, 62.6% were male, 77.9% were white, and 76.2% were 50-79 years old. For overall case-to-MDC proximity, nearly half (44.9%) of all geocoded cases in the US lived >50 miles from an MDC, including approximately a quarter who lived >100 miles from an MDC. There was a statistically significant difference between distance to MDC by race and age group.
conclusionsThe high percentage of those living more than 50 miles from the nearest specialized clinic underscores one of the many challenges of ALS. Having better access to care, whether at MDCs or through other modalities, is likely key to increasing survivability and obtaining appropriate end-of-life treatment and support for people with ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.